The administration of estrogens for gonadal dysgenesis is sometimes associated with the development of endometrial neoplasms.
Estrogen dificiency is associated whith a lack of devolopment of secondary sexual characteristics, genital infantilism, genital atrophy and osteoporosis. Appropriate longterm estrogen replacement therapy for such patients, especially those with gonadal dysgenesis is necessary for proper physical and psychological development. However, hyperplasia or carcinoma of the endometrium bas been associated with patients undergoing long-term estrogen therapy [1-5, 7-12]. Furthermore, high dose estrogen use has also been associated with myocardial infarction, thromboembolic disease, cerebrovascular accidents, altered lipid and carbohydrate metabolism, hypertension, liver adenoma and so on. The optimal dosage of estrogen which will minimize these side effects and yet provide the desired physiological benefit has not been well established.
This study was conducted in an attempt to individualize the appropriate dosage of estrogen for patients with gonadal dysgenesis requiring estrogen replacement therapy.
Material and Method
Six patients with gonadal dysgenesis were studied (Table  I) 5pg/ml and the intra-assay coefficient of variation was less than 7% between 30 and 300pg/ml. The inter-assay coefficient of variation was less than 16% .
Results
The (Fig. 1) .
After vaginal application of one tablet of Hormonin No.2, the average peak levels of estrogens were obtained at around four hours. The 24-hour mean concentrations for E1, E2 and E3 were 237, 480 and 38pg/ml, respectively. The E1/E2 concentration ratio was 0.5 (Fig. 1) TE2Eq=(120•~0.4+150+20•~0.1)•}100 =200•}100(pg/ml) .
On the average, estrogen levels are higher in the luteal phase and during this phase progesterone is also present. Hence reasonable estrogen/progestin replacement therapy for young women without ovarian function together with a progestatinal agent in the latter half of each cycle.
The relative biological potencies of E1 , E2 and E3 are different in various target organs. Therefore, adjustment of serum level alone may not be sufficient to establish the optimal estrogen dosage for a given patient . Various other biological effects of estrogens will have to be taken into consideration when adjustment of the estrogen dosage is attempted. The parameters of these biological effects include: symptoms and signs of estrogen deficiency, Maturation Index, gonadotropin levels, bone integrity and so forth. This fact should be considered especially when estrogens are given orally, because intestinal conversion of E2 to E1 [13] makes the E1 level about 5times higher than the E2 level and this ratio is not physiologic. On the other hand, the E1/E2 ratio achieved by the vaginal route seems to be more physiologic since this route of administration avoids intestinal conversion of E2 to E1. One of the disadvantages of this route is the shorter duration of peak level as compared to oral route. However, this difficulty can be overcome by twice a day administration.
The principle of estrogen therapy approximating the estrogen level of a normal menstruating woman has application not only to patients with gonadal dysgenesis but to patients with other estrogen deficient conditions, such as hypogonadotrophic hypogonadism and premature ovarian failure. The cyclic administration of progestational agents may mitigate the dangers of estrogen therapy. However endometrial carcinoma has been reported even with cyclic estrogen/progestin therapy [10] . Therefore it is advisable to periodically sample the endometrium to detect any hyperplastic changes early, at which point a decrease in the estrogen dosage and/ Table I  GONADAL  DYSGENESIS 
